Japan Central Nervous System (CNS) Drug Market was valued at USD 9.86 Billion in 2022 and is projected to reach USD 13.88 Billion by 2030, growing at a CAGR of 4.5% from 2024 to 2030.
Japan's Central Nervous System (CNS) drug market has experienced significant growth, driven by an aging population and increasing prevalence of neurological disorders. In 2020, the market generated approximately USD 7.6 billion in revenue, with projections estimating it will reach USD 12.9 billion by 2028, reflecting a compound annual growth rate (CAGR) of 6.8%.
Key therapeutic areas contributing to this growth include:
Mental Health: Accounting for 42.82% of the market share in 2020, this segment addresses conditions such as depression and schizophrenia.
Neurodegenerative Diseases: This segment is expected to be the fastest-growing, focusing on diseases like Alzheimer's and Parkinson's.
Several Japanese pharmaceutical companies have been instrumental in addressing these challenges:
Eisai Co. Ltd.: Known for developing Aricept and Leqembi for Alzheimer's disease, and Fycompa for epilepsy.
Otsuka Holdings: Offers treatments like Abilify and Rexulti for schizophrenia and depression.
Takeda Pharmaceutical Company: Markets Azilect for Parkinson's disease and Trintellix for major depressive disorder in Japan.
Industry requirements to sustain and enhance this growth include:
Regulatory Adaptations: Historically, Japan's stringent drug approval processes, including mandatory local clinical trials, have delayed the availability of new treatments. However, recent regulatory relaxations aim to expedite approvals, especially for drugs addressing unmet medical needs.
Investment in Research and Development (R&D): Continuous innovation is vital. Companies are encouraged to invest in R&D to develop novel therapies and improve existing ones.
Adherence to Good Manufacturing Practices (GMP): Ensuring product quality and safety is paramount. Compliance with GMP standards is essential for maintaining trust and efficacy in CNS therapeutics.
Strategic Collaborations and Acquisitions: To bolster their CNS drug portfolios, companies are engaging in strategic partnerships. For instance, Bain Capital's recent acquisition of Mitsubishi Tanabe Pharma for approximately $3.37 billion aims to accelerate drug development in Japan, particularly for rare diseases.
In conclusion, the Japan CNS drug market is poised for substantial growth, driven by demographic trends and a focus on neurological health. By addressing industry requirements such as regulatory reforms, R&D investment, GMP compliance, and strategic collaborations, the sector can continue to innovate and meet the evolving needs of patients.
Get an In-Depth Research Analysis of the Japan Central Nervous System (CNS) Drug Market Size And Forecast [2025-2032]
Johnson & Johnson
Pfizer Inc
Novartis AG
GSK
Eli Lilly
Teva
Otsuka Pharmaceutical Co.
Ltd
Biogen Inc
Boehringer Ingelheim
Roche
UCB
Tekeda
Shanghai Fosun
Jiangsu Nhwa Pharmaceutical Co.
Ltd.
By the year 2030, the scale for growth in the market research industry is reported to be above 120 billion which further indicates its projected compound annual growth rate (CAGR), of more than 5.8% from 2023 to 2030. There have also been disruptions in the industry due to advancements in machine learning, artificial intelligence and data analytics There is predictive analysis and real time information about consumers which such technologies provide to the companies enabling them to make better and precise decisions. The Asia-Pacific region is expected to be a key driver of growth, accounting for more than 35% of total revenue growth. In addition, new innovative techniques such as mobile surveys, social listening, and online panels, which emphasize speed, precision, and customization, are also transforming this particular sector.
Get Discount On The Purchase of the Japan Central Nervous System (CNS) Drug Market Size And Forecast [2025-2032]
Growing demand for below applications around the world has had a direct impact on the growth of the Japan Central Nervous System (CNS) Drug Market
SSRIs (Selective Serotonin Reuptake Inhibitors)
SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors)
Tricyclic Antidepressants
Monoamine Oxidase Inhibitors (MAOIs)
Depression
Schizophrenia
Anxiety Disorders
Epilepsy
Bipolar Disorder
Neuropathic Pain
Selective Serotonin
Norepinephrine Reuptake
Oral
Intravenous
Intramuscular
Transdermal
Inhalation
Buccal
Male
Female
Asia-Pacific (China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Malaysia and Vietnam)
For More Information or Query, Visit @ Japan Central Nervous System (CNS) Drug Market Research Analysis
1. Introduction of the Japan Central Nervous System (CNS) Drug Market
Overview of the Market
Scope of Report
Assumptions
2. Executive Summary
3. Research Methodology of Verified Market Reports
Data Mining
Validation
Primary Interviews
List of Data Sources
4. Japan Central Nervous System (CNS) Drug Market Outlook
Overview
Market Dynamics
Drivers
Restraints
Opportunities
Porters Five Force Model
Value Chain Analysis
5. Japan Central Nervous System (CNS) Drug Market, By Type
6. Japan Central Nervous System (CNS) Drug Market, By Application
7. Japan Central Nervous System (CNS) Drug Market, By Geography
Asia-Pacific
China
Japan
Korea
India
Australia
Indonesia
Thailand
Philippines
Malaysia and Vietnam
8. Japan Central Nervous System (CNS) Drug Market Competitive Landscape
Overview
Company Market Ranking
Key Development Strategies
9. Company Profiles
10. Appendix
About Us: Verified Market Reports
Verified Market Reports is a leading Research and Consulting firm servicing over 5000+ clients. We provide advanced analytical research solutions while offering information-enriched research studies. We also offer insights into strategic and growth analyses and data necessary to achieve corporate goals and critical revenue decisions.
Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance using industrial techniques to collect and analyze data on more than 25,000 high-impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.
Contact us:
Mr. Edwyne Fernandes
US: +1 (650)-781-4080
US Toll-Free: +1 (800)-782-1768
Website: https://www.verifiedmarketreports.com/